AAMU
SPHS

Amundi Asset Management US’s Sophiris Bio, Inc. SPHS Stock Holding History

Amundi Asset Management US’s Portfolio SPHS Stock Details SPHS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-23,800
Closed -$66K – 1739
2018
Q3 		$66K Buy
+23,800
New +$67.7K ﹤0.01% 1548

Other funds holding SPHS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BO
BRR OpCo Columbus, Ohio $814M AUM 9.75% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Amundi Asset Management US's SPHS Position: Q4 2018 in Review

Amundi Asset Management US sold out of Sophiris Bio, Inc. (SPHS) in Q4 2018, closing a stake of 23,800 shares — an estimated $66K sold.

Amundi Asset Management US first reported a position in SPHS in Q3 2018 and held it in 1 quarter. The position peaked at $66K in Q3 2018. 31 funds tracked by Wall St. Rank hold SPHS as of Q4 2018.

  • Amundi Asset Management US reported no remaining Sophiris Bio, Inc. position as of Q4 2018 after selling out during the quarter.
  • Amundi Asset Management US sold 23,800 Sophiris Bio, Inc. shares in Q4 2018, an estimated $66K.
  • Amundi Asset Management US first reported a position in Sophiris Bio, Inc. in Q3 2018 and held it in 1 quarter.
  • Amundi Asset Management US's Sophiris Bio, Inc. position peaked at $66K in Q3 2018.
  • 31 funds tracked by Wall St. Rank held Sophiris Bio, Inc. as of Q4 2018.

Based on Amundi Asset Management US's 13F filing for Q4 2018, filed 14 Feb 2019.